Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-positive Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer
Interventions: DRUG: Neratinib|DRUG: Letrozole (L) or Anastrozole (A)|DRUG: Trastuzumab
Sponsor: Ruth O'Regan
Collaborators: Puma Biotechnology, Inc.|University of Rochester